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inhabitants). Setting 2 included all prescriptions provided by the
Geneva University Hospitals to outpatients. RESULTS: Despite
the commercialisation of citalopram generics as of October
2002, and despite the marketing of escitalopram as of March
2002, the total amount of citalopram prescribed remained con-
stant from 2000 to 2007. The prescription of escitalopram
increased from 2002 onwards. In January 2007, the volume of
prescription in setting 1 was 12 Daily Deﬁned Doses per 1,000
inhabitants (DDD/1000) for citalopram and 8 DDD/1000 for
escitalopram. In setting 2, the DDD/1000 was around 1 for both
citalopram and escitalopram. Around 76% of citalopram pre-
scriptions were dispensed as generics in both settings. Consider-
ing all available dosages and conditioning forms in Switzerland,
proprietary citalopram is 1 Euro per tablet more expensive than
generic citalopram; escitalopram is 0.8 to 1 Euro per tablet more
expensive than generic citalopram, depending on the size of the
package. From April 2006 to March 2007, had only generic
citalopram been prescribed instead of escitalopram, the total
estimated savings would have been 0.95 million Euros. CON-
CLUSION: Prescription of generic citalopram instead of escit-
alopram could lead to major savings.
PMH19
COMORBIDITY AND COSTS IN GENERALIZED ANXIETY
DISORDERS AND FIBROMYALGIA SYNDROME INTHE
PRIMARY CARE SETTING (PCS):A COMPARISON OFTWO
DISORDERS WITH HIGH DEMAND OF CARE
Blanca-Tamayo M1, Sicras-Mainar A2, Navarro-Artieda R3,
Rejas-Gutiérrez J4
1Badalona Serveis Assistencials, Badalona, Barcelona, Spain, 2Badalona
Servicios Asistenciales, Badalona, Barcelona, Spain, 3Hospital Germans
Trias y Pujol, Badalona, Barcelona, Spain, 4Pﬁzer Spain, Madrid, Spain
OBJECTIVES: To evaluate the comorbidity and economical
impact of two disorders of high demand of care in PCS: Gen-
eralized Anxiety Disorder (GAD) and Fibromyalgia Syndrome
(FMS). METHODS: A retrospective multicenter population-
based study was carried out, involving outpatient records of
men and women above 20 years managed at seven PCSs during
year 2006. Main outcomes measures were comorbidity as
determined by Charlson index, health resources utilization
(visits, diagnostic/therapeutic measures, referrals and drugs),
days of work absenteeism (transient disability, TD), and corre-
sponding costs. Four groups were established for comparison:
population, FMS, GAD, both). The statistical analysis included
a bivariate (ANOVA; Spearman-correlation) and analysis of
covariance (ANCOVA). RESULTS: A total of 63,526 patients
were included, aged 49.2  17.8 years; 54.2% women. GAD
group: 3,385 patients (5.3%; CI: 5.1–5.5%), age 55.3  16.7
years; 70.5% women. FMS group: 904 patients, age 54.3  9.8
years; 96.5% women. Both diagnoses: 177 patients, age
53.4  11.1 years; 97.7% women. Depression was associated
to the presence of FMS (42.4%) or both disorders (29.4%);
p < 0.001. The Charlson index in GAD was 0.2  0.5, versus
0.3  0.6 in FMS; p < 0.001. Compared with the population
group, the other three groups were older and had more comor-
bidity, p < 0.001. The mean adjusted monetary costs per patient
per year were; €555.92; €909.02; €817.69 and €1140.88,
respectively (p < 0.001). Mean transient disability days were,
respectively: 55.5, 204.8, 123.9, and 256.3 days, p < 0.001.
CONCLUSION: Patients with GAD are older and have greater
comorbidity when associated with FMS. Adjusted costs are
higher in FMS than in GAD, and increases (more than 2-fold)
when the two disorders are combined, versus the general
population.
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OBJECTIVES: To determine whether subjects with major
depressive disorder (MDD) that switch/augment therapy have
higher economic burden compared to those who stay on therapy.
METHODS: Data were derived from a national-employment-
based medical and pharmacy claims database. Index date
was deﬁned based on pre-speciﬁed antidepressant prescription
claims between January 1, 2003-June 30, 2005. Subjects were
treatment-naïve 6-months prior to index-date, continuously
enrolled, and had at least one outpatient-based medical claim for
MDD (ICD-9 = 296.2x/296.3x) during study period. Study
cohorts [switchers/augmenters/maintainers] were deﬁned based
on antidepressant prescription reﬁll pattern 12-months post
index therapy. Per-patient-per-year (PPPY) post-index resource
use and costs were compared univariately (Wilcoxon tests) and
multivariately (generalized-linear-model). All statistical compari-
sons were made in reference to the maintainer cohort at a 0.05
family-wise type I error. RESULTS: Of 47,178 individuals who
meet the study criteria, 29% (n = 13,682), 12% (n = 5,829), and
59% (n = 27,667) were classiﬁed as switchers, augmenters, and
maintainers, respectively. Baseline characteristics (age, gender,
region, comorbidity and payer/plan-type) were similar across
the three cohorts. Total post-index PPPY medical visits for
switchers, augmenters, and maintainers were 26 (SD = 20.8), 28
(SD = 23.0), and 18 (SD = 17.0) for ambulatory, 1.2 (SD = 3.9),
1.4 (SD = 4.8) and 0.84 (SD = 3.3) for ER, and 0.31 (SD = 0.78),
0.32 (SD = 0.87) and 0.12 (SD = 0.46) for inpatient services,
respectively. A similar patternwas observed for depression-related
PPPY resource-use with higher (p < 0.0001) visits in the switcher/
augmenter cohorts vs. maintainer cohort. Average total and
depression-related health care costs were 1.52 to 2.06 times
(p < 0.001) and 1.54 to 2.03 times (p < 0.001) greater for switch-
ers ($8512 and $859)/augmenters ($8624 and $847) vs. maintain-
ers ($5600 and $417) after controlling for baseline characteristics,
costs and post-index adherence to antidepressants. CONCLU-
SION: MDD subjects that change therapy within 12-months of
treatment initiation have higher resource use and costs compared
to those who stay on the same therapy. Further research needs to
be conducted to determine the impact on indirect costs.
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OBJECTIVES: Risperidone long-acting injectable (RLAI) is the
only long-acting atypical antipsychotic for schizophrenia. The
cost effectiveness of RLAI compared to olanzapine and haloperi-
dol depot was analyzed in a Swedish treatment setting, using a
discrete event simulation (DES) model. METHODS: Following
interviews with a Swedish expert panel an existing DES model,
which simulates individual schizophrenia patients over a ﬁve-
year time period, was adapted to reﬂect schizophrenia treatment
and comply with local health-economic guidelines. Inputs for the
model were derived from clinical trial data, literature, database
analysis and expert opinion. Cost estimates depend on treatment
and treatment location; quality of life depends on symptom
severity (measured by the PANSS score) and side-effects. A mul-
Abstracts A293
